Redmile Group, LLC Atara Biotherapeutics, Inc. Transaction History

Redmile Group, LLC

$1.53 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.44 - $1.22 $69,019 - $191,372	156,863 Added 1.72%	9,263,309 $6.39 Million
Q4 2023 Feb 14, 2024	BUY	$0.23 - $1.74 $703,414 - $5.32 Million	3,058,323 Added 50.57%	9,106,446 $4.64 Million
Q2 2023 Aug 14, 2023	BUY	$1.5 - $3.04 $654,100 - $1.33 Million	436,067 Added 7.77%	6,048,123 $9.74 Million
Q1 2023 May 15, 2023	SELL	$2.8 - $5.46 $1.77 Million - $3.44 Million	-630,700 Reduced 10.1%	5,612,056 $16.3 Million
Q2 2022 Aug 15, 2022	SELL	$4.69 - $9.84 $14,796 - $31,045	-3,155 Reduced 0.05%	6,242,756 $48.6 Million
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $1.62 Million - $3.24 Million	-191,866 Reduced 2.98%	6,245,911 $58 Million
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $418,950 - $566,865	-28,500 Reduced 0.44%	6,437,777 $101 Million
Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $200,233 - $298,930	16,700 Added 0.26%	6,466,277 $116 Million
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $5.62 Million - $7.22 Million	-435,656 Reduced 6.33%	6,449,577 $100 Million
Q1 2021 May 17, 2021	BUY	$14.0 - $20.72 $310,282 - $459,217	22,163 Added 0.32%	6,885,233 $98.9 Million
Q4 2020 Feb 16, 2021	SELL	$12.67 - $26.23 $960,386 - $1.99 Million	-75,800 Reduced 1.09%	6,863,070 $135 Million
Q3 2020 Nov 16, 2020	BUY	$11.92 - $15.87 $1.14 Million - $1.52 Million	95,500 Added 1.4%	6,938,870 $89.9 Million
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $11.7 Million - $23.1 Million	1,550,000 Added 29.28%	6,843,370 $99.7 Million
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $3.67 Million - $11.5 Million	644,800 Added 13.87%	5,293,370 $45 Million
Q4 2019 Feb 14, 2020	BUY	$10.89 - $16.79 $1.4 Million - $2.16 Million	128,853 Added 2.85%	4,648,570 $76.6 Million
Q3 2019 Nov 14, 2019	SELL	$12.03 - $19.94 $976,836 - $1.62 Million	-81,200 Reduced 1.76%	4,519,717 $63.8 Million
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $2.2 Million - $4.74 Million	115,500 Added 2.58%	4,600,917 $92.5 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $41.74 $2.01 Million - $2.96 Million	70,800 Added 1.6%	4,485,417 $178 Million
Q4 2018 Feb 14, 2019	BUY	$30.9 - $42.97 $6.05 Million - $8.42 Million	195,900 Added 4.64%	4,414,617 $153 Million
Q3 2018 Nov 14, 2018	BUY	$35.05 - $43.5 $3.23 Million - $4.01 Million	92,100 Added 2.23%	4,218,717 $174 Million
Q2 2018 Aug 14, 2018	SELL	$35.15 - $51.45 $3.85 Million - $5.63 Million	-109,400 Reduced 2.58%	4,126,617 $152 Million
Q1 2018 May 15, 2018	BUY	$18.0 - $48.35 $25.6 Million - $68.7 Million	1,420,029 Added 50.43%	4,236,017 $0
Q4 2017 Feb 14, 2018	SELL	$13.2 - $18.1 $973,130 - $1.33 Million	-73,722 Reduced 2.55%	2,815,988 $51 Million
Q3 2017 Nov 14, 2017	BUY	$13.25 - $17.05 $38.3 Million - $49.3 Million	2,889,710	2,889,710 $47.8 Million

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account